Development of Lipid Nanoparticles for On-Target Genome Editing

The novel development of ipid nanoparticle-mediated delivery of genome editing complexes is thriving and the associated clinical trials is gaining success in clinical trial phase I by targeting the genetic mutation in transthyretin amyloidosis led by Intellia showing the tremendous interest to the academia and industry. However, the remaining challenges like endosomal escape, targeted delivery and subcellular distribution of lipid nanoparticles are not fully understood among most researchers. Dr. Qiaobing Xu and his research assistant professor Dr. Yamin Li, conducted an extensive research on the synthesis of lipid-based nanoparticles using combinatorial library strategy for the delivery of drug, therapeutic proteins including gene editing complexes. Therefore, in the third 30-min scientific talk in the central theme “Innovations in targeting genetic blueprints in vivo”, the proposed lecture-based presentation will be given by the invited speaker Dr. Qiaobing Xu or Dr. Yamin Li, from Tufts University, and will focus on the most recent advance of the development of lipid nanoparticles for on-target genome editing, highlighting the needs for in vivo lipid nanoparticle-mediated intracellular protein delivery